24 January 2024

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by **Firebrick Pharma Limited** (**Issuer** or **Company**) (**ASX:FRE**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Act**").

The Company has issued 900,000 ordinary fully paid shares upon exercise of unlisted options at an exercise price of $0.0067 per ordinary fully paid share ("**Issued Shares**")

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;

2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and

3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:

    a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;

    b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:

        i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

        ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully

Stephen Buckley

Company Secretary

About Firebrick Pharma

Firebrick is a pharmaceutical company with the mission to develop and commercialise a povidone-iodine nasal spray. The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the US, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com